Not too long ago, “special populations” of hepatitis C infection referred to patients failing to achieve SVR with the currently available DAA therapies. Now, as therapeutic efficacy has progressed, the concept of special populations has shifted focus to include treatment of people affected by HCV-related hepatic and extrahepatic manifestations.
In this issue, Dr. Paul Martin and Dr. Kalyan Ram Bhamidimarri of the University of Miami analyze recent publications on managing HCV complications in special populations — patients with chronic kidney disease, cryoglobulinemia, cirrhosis, and HIV coinfection, and those receiving transplant organs from HCV-infected donors.
Professor of Medicine
Division of Infectious Diseases
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology and Hepatology
Johns Hopkins School of Medicine
Director of Hepatology and Liver Center
Vice Chief, Gastroenterology
Kevin and Polly Maroni Research Scholar
Massachusetts General Hospital
Harvard Medical School
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: September 28, 2018
Expiration date: September 27, 2020